JNJ Stock Jumps on FDA Clearance of MONARCH QUEST 3 Upgrade

J&J's MONARCH QUEST 3 software update has received FDA clearance, expanding its capabilities in robotically assisted bronchoscopy technology.

The update adds AI-powered planning and stronger navigation capabilities to the company's existing platform.

The MONARCH Platform supports direct visualization during procedures and helps physicians navigate airways and reach targeted areas for diagnostic biopsies.

J&J shares gained 0.46% to $261.55 after receiving the clearance, which supports broader use in advanced lung diagnostic care.